2017

Purdue Pharma invests in oncology R&D

Wednesday, November 15, 2017

Purdue Pharma announced completion of significant oncology related investments as part of its ongoing efforts to diversify its scientific research into areas of high unmet medical need. Through these investments, executed over a multi-year period and capped recently in 2017, Purdue is establishing a portfolio of drug candidates with the potential to deliver new cancer therapies to patients within the next five years.

[Read More]

FDA approves pill with sensor to track patients adherence

Tuesday, November 14, 2017

The FDA approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

[Read More]

Sage’s postpartum depression drug Brexanolone hits primary endpoints

Tuesday, November 14, 2017

Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced positive top-line results from two phase III clinical trials with its proprietary i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 202B in severe postpartum depression (PPD) and Study 202C in moderate PPD. Brexanolone achieved the primary endpoint in both trials, a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D) total score compared to placebo at 60 hours (Study 202B: p=0.0242 for 90 µg/kg/h dose and p=0.0011 for 60 µg/kg/h dose; Study 202C: p=0.0160 for 90 µg/kg/h dose). Patients treated with brexanolone demonstrated mean reductions from baseline in HAM-D total scores of 14 to 20 points at 60 hours maintained to 30 days in both trials. Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies.

[Read More]

Pertinax Pharma appoints former Sanofi chairman Nigel Brooksby as Chairman

Tuesday, November 14, 2017

Pertinax Pharma announces that Nigel Brooksby has been appointed as chairman of the company. His chief responsibilities will be to assist in corporate, strategic and business development moves into its commercialization phase following the launch last month of Pertinax. This unique technology which enables controlled and sustained release of the antimicrobial, chlorhexidine (CHX) has wide ranging potential applications, spanning the wound care, medical device, dental and veterinary markets.

[Read More]

Helmsley Charitable Trust backs Vivli with funding to deliver data-sharing platform

Tuesday, November 14, 2017

Vivli has secured funding from The Leona M. and Harry B. Helmsley Charitable Trust to deliver an innovative data-sharing platform, which will make it easier to find, host and analyze clinical trial data across disease areas to accelerate medical research. This funding will augment what Vivli has already received and ensure that the platform is available for public use in 2018.

[Read More]

Marken launches app for clinical patients

Tuesday, November 14, 2017

Marken introduced the launch of a new online tool, Marken Viseo, which will allow patients to track their home deliveries of clinical trial materials and the pickup of their biological specimens via their mobile device or personal computer.

[Read More]